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Background: Despite the importance of abnormalities in lipoprotein metabolism in clinical canine medicine, the
fact that most previously used methods for lipoprotein profiling are rather laborious and time-consuming has been
a major obstacle to the wide clinical application and use of lipoprotein profiling in this species. The aim of the
present study was to assess the feasibility of a continuous lipoprotein density profile (CLPDP) generated within a
bismuth sodium ethylenediaminetetraacetic acid (NaBiEDTA) density gradient to characterize and compare the
lipoprotein profiles of healthy dogs of various breeds, healthy Miniature Schnauzers, and Miniature Schnauzers with
primary hypertriacylglycerolemia. A total of 35 healthy dogs of various breeds with serum triacylglycerol (TAG) and
cholesterol concentrations within their respective reference intervals were selected for use as a reference
population. Thirty-one Miniature Schnauzers with serum TAG and cholesterol concentrations within their respective
reference intervals and 31 Miniature Schnauzers with hypertriacylglyceridemia were also included in the study.
Results: The results suggest that CLPDP using NaBiEDTA provides unique diagnostic information in addition to
measurements of serum TAG and cholesterol concentrations and that it is a useful screening method for dogs with
suspected lipoprotein metabolism disorders. Using the detailed and continuous density distribution information
provided by the CLPDP, important differences in lipoprotein profiles can be detected even among dogs that have
serum TAG and cholesterol concentrations within the reference interval. Miniature Schnauzers with serum TAG and
cholesterol concentrations within the reference interval had significantly different lipoprotein profiles than dogs of
various other breeds. In addition, it was further established that specific lipoprotein fractions are associated with
hypertriacylglyceridemia in Miniature Schnauzers.
Conclusions: The results of the present study suggest that density gradient ultracentrifugation using NaBiEDTA is a
useful screening method for the study of lipoprotein profiles in dogs. Therefore, this method could potentially be
used for diagnostic purposes for the separation of dogs suspected of having lipoprotein abnormalities from healthy
dogs.
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The investigation of lipoprotein profiles in serum or
plasma from healthy dogs has been the subject of occa-
sional research since the 1940s [1-4]. Much of our current
knowledge on canine lipoproteins originates from studies
reported in the 1970s, which investigated dogs as possible
models for human cardiovascular disease [3-5]. More re-
cent studies investigated canine lipoproteins in association
with several disease conditions or physiologic stages
[5-11]. These studies have provided important information
on the major serum lipoprotein fractions found in dog
serum or plasma, namely chylomicrons, very low density
lipoproteins (VLDL), low density lipoproteins (LDL), and
high density lipoproteins (HDL).
The methodologies used to study canine lipoproteins in
the past included electrophoresis, sequential density gradi-
ent centrifugation, and size exclusion methods [3-11].
These methods generally suffered from lack of resolution
and could not capture detailed information related to the
continuous density distribution of lipoproteins. In addition,
highly specialized techniques of analytical ultracentrifuga-
tion and imaging were required to measure continuous
density information. Technical and temporal barriers that
limited research into the utility of continuous lipoprotein
density profiles (CLPDP) in human and veterinary medi-
cine have been largely overcome by recent developments
in gradient-generating chemistries, centrifugation and im-
aging technologies [12,13]. At present, detailed and highly
reproducible CLPDP are readily available [13]. The analy-
tical resolution, speed and simplicity of these improved
methods suggest that CLPDP may be suitable for rapid
clinical and discovery purposes, particularly in settings
where serum or plasma lipid concentrations alone are non-
definitive. Such situations occur in both human [14,15] and
animal [16,17] populations. In research settings there is
high utility in the ability to rapidly screen profiles to identify
interesting density subfractions for further compositional
characterization [18,19]. Pragmatically, novel methods for
lipoprotein analysis are slowly introduced to clinical prac-
tice for diagnostic purposes and used in clinical studies for
risk assessment using combinations of analytical and statis-
tical methods [18,19]. Such novel methods have not been
previously applied to dogs, and therefore the feasibility of
application and usefulness of these techniques is not known
in this species.
Diseases that affect lipoprotein metabolism are both
common and clinically important in dogs [20]. The most
common disorders of lipoprotein metabolism in dogs are
secondary to other diseases, such as diabetes mellitus,
hypothyroidism, and hyperadrenocorticism [20]. Mini-
ature Schnauzers are particularly interesting with regard
to their serum lipids and lipoprotein profiles. Primary
hypertriacylglycerolemia is a common condition in Mini-
ature Schnauzers in the United States. In one study,hypertriacylglycerolemia was present in 32.8% of 192
Miniature Schnauzers investigated [21]. In this breed, hyper-
lipidemia, and more specifically hypertriacylgly-cerolemia,
might be associated with diseases such as hepatobiliary di-
sease, pancreatitis, insulin resistance, and ocular disease
[16,17,20,22]. The biochemical, metabolic, and genetic
bases of hypertriacylglycerolemia in Miniature Schnauzers
have not been identified yet. Previous studies have shown
that hypertriacylglycerolemia in Miniature Schnauzers is
mainly characterized by an abnormal accumulation of
VLDL with or without hyperchylomicronemia [10].
Despite the importance of abnormalities in lipoprotein
metabolism in clinical canine medicine, the fact that
most previously used methods for lipoprotein profiling
are rather laborious and time-consuming has been a
major obstacle to the wide clinical application and use of
lipoprotein profiling in this species. Newer CLPDP tech-
niques are not constrained by specific density intervals,
require small volumes of serum or plasma, and can be
completed in a few hours [12,13]. Coupled with rapid
imaging of resolved lipoproteins and appropriate statis-
tical analysis, these techniques are better able to capture
diagnostic value from more fully resolved lipoprotein
subclasses. To this end, a convenient, economical, and
robust method of lipoprotein profiling that could be used
for diagnostic purposes in clinical practice would be
highly desirable. The aim of the present study was to as-
sess the feasibility of a novel density gradient ultracentri-
fugation method in dogs, and to evaluate the ability of
this method to separate healthy dogs of various breeds,
healthy Miniature Schnauzers, and Miniature Schnauzers
with primary hypertriacylglycerolemia based on their
lipoprotein profiles.Methods
All owners participating in the study signed an informed
owner consent form. The study protocol was reviewed
and approved by the Clinical Research Review Committee
at Texas A&M University (CRRC#08-37).
Animals
Group 1: reference population composed of dogs of various
breeds
A total of 35 healthy dogs of various breeds with serum
triacylglycerol (TAG) and cholesterol concentrations within
their respective reference intervals were selected for use as
a reference population. Inclusion criteria included being a
breed other than Miniature Schnauzer, being a breed that
has not been reported to have any lipoprotein metabolism
disorders [20], absence of any clinical signs at the time of
blood collection and no history of disease or current use of
drugs known to affect lipid metabolism. Serum TAG and
cholesterol concentrations were measured in all dogs.
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Samples were selected from a pool of >300 samples from
Miniature Schnauzers that were collected as part of several
ongoing projects related to hypertriacylglyceridemia in this
breed. All Miniature Schnauzers that were included in
group 2 had to have absence of any clinical signs at the time
of blood collection and no history of disease or use of drugs
known to affect lipid metabolism. Serum TAG and choles-
terol concentrations were measured in all dogs in group 2,
and were used to categorize dogs into 2 subgroups.
Group 2A – normolipemic miniature schnauzers
Thirty-one Miniature Schnauzers with serum TAG and
cholesterol concentrations within their respective refe-
rence intervals were included. These dogs were selected to
be 7 years of age or older. An age criterion was imposed
in order to minimize the possibility of them developing
hyperlipidemia in the future because age is known to
affect lipoprotein concentrations and distribution in this
breed. Miniature Schnauzers that have not developed
hypertriacylglyceridemia by the age of 7 years are unlikely
to develop hypertriglyceridemia in the future [20].
Group 2B – hypertriacylglyceridemic miniature
schnauzers
Thirty-one Miniature Schnauzers with serum TAG con-
centrations above the upper limit of the reference interval
(>108 mg/dL) were also included in the study. In addition,
in this group of dogs, serum canine specific pancreatic lip-
ase (Spec cPL), glucose, total T4, and free T4 (in cases in
which serum total T4 was below the lower limit of the ref-
erence interval) concentrations were measured to evaluate
those dogs for any potential underlying diseases that may
be responsible for hypertriacylglyceridemia. Based on the
historical information for each dog and the results of the
tests performed, all hypertriacylglyceridemic dogs enrolled
in this study were diagnosed as having primary idiopathic
hypertriacylglyceridemia of Miniature Schnauzers [20,21].
Blood collection and handling
Owners living in relative proximity to the Gastrointestinal
Laboratory at Texas A&M University were instructed to
schedule an appointment for the blood collection at that
location. Owners that could not come to Texas A&M for
the blood collection were each sent a styrofoam box
containing ice packs and the material necessary for blood
collection, and were asked to schedule an appointment
with their veterinarian for the blood collection. All owners
were instructed not to feed their dogs for at least 12 hours
before the scheduled blood collection. Ten milliliters of
blood were collected from each dog into a red-top tube
(with no additive). Immediately after clot formation, the
samples were centrifuged and the serum was separated
from the clot. Samples not collected at Texas A&MUniversity were sent to the Gastrointestinal Laboratory
packed on ice by overnight courier. Serum samples were
stored at −80°C until analyzed.
Questionnaires and consent forms
Owners of all dogs were asked to complete a question-
naire for each dog. Questions covered date of birth, sex,
body weight, current diet(s), current medications, and
current and past health history of the dogs. Question-
naires from all dogs were reviewed to determine whether
the dogs fit the inclusion criteria for each group.
Assays
Serum TAG (reference interval: 26–108 mg/dL), cholesterol
(reference interval: 124–335 mg/dL), and glucose (reference
interval: 60–120 mg/dL) concentrations were measured by
automated enzymatic assaysa. Serum Spec cPL concentra-
tions (reference interval: ≤200 μg/L) were measured using
an analytically validated immunoassay as described else-
where [23]. Serum total T4 concentrations were measured
by a solid-phase chemiluminescent competitive assayb.
Serum free T4 concentration was measured using a com-
mercial equilibrium dialysis radioimmunoassayc.
Lipoprotein profile analysis
Lipoprotein profiling was carried out using a bismuth
sodium ethylenediaminetetraacetic acid (NaBiEDTA)
density gradient ultracentrifugation method as previ-
ously described with some modifications [24]. The so-
dium salt of BiEDTA has been described as a novel
solute forming self-generating density gradient during
ultracentrifugation of serum samples for the separation
of lipoproteins [24]. Briefly, for each sample, 1,284 μL of
a 0.18M NaBiEDTAd gradient solution was added into a
1.5 mL tube. The fluorescent probe 6-((N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)amino)hexanoyl)sphingosinee was
reconstituted with 1 g/mL DMSO and ten μL of the 1
mg/mL solution were added to each tube to label the li-
poproteins. Finally, 6 μL of serum was added to each
tube to give a total volume of 1,300 μL. The mixture was
vortexed at 1,400 rpm for 10 sec and 1,150 μL was
transferred into an ultracentrifuge tubef as this is the
maximal amount of fluid retained during ultracentrifu-
gation in the open top tube. The mixture was allowed to
incubate for 30 minutes at 5°C to allow for the fluores-
cent probe to saturate the lipoproteins. The solution was
then centrifuged at 120,000 rpm, at 5°C, for 6 hours in a
Beckman Optima ultracentrifugeg with a 30° fixed angle
TLA 120.2 rotorh. A quality control sample was included
in each run to verify proper operating conditions were
achieved. Immediately after ultracentrifugation, the top
of each sample was carefully layered with 250 mL of
hexane to remove optical interference from the menis-
cus and imaged without delay.
Xenoulis et al. BMC Veterinary Research 2013, 9:47 Page 4 of 11
http://www.biomedcentral.com/1746-6148/9/47For imaging, each tube was placed in a custom, in-
house imaging instrument as previously described [24].
The samples were imaged using a custom-built fluores-
cence imaging system consisting of a digital camerai with
a MH-100 metal halide continuous light sourcej, located
in a dark room. Two filtersk matching the excitation
(blue-violet filter centered at 407 nm) and emission
(a yellow emission long pass filter with a cut-on wave-
length of 515 nm) characteristics of NBD C6-cermide
were used. A gain of 1.0000, a target intensity of 30%,
and an exposure time of 53.3 ms were selected. In order
to be analyzed, the image of the each tube following ultra-
centrifugation was converted to a density profile using a
commercially available software programl. A tube coor-
dinate scale was established where 0.0 mm is the top of
the tube and 34.0 mm is the bottom of the tube [24].
The average fluorescent intensity was then plotted as a
function of tube coordinate.Statistical analysis
Commercial statistical software packages were used for all
statistical analysesm,n,o. Data were analyzed for normal dis-
tribution using the Shapiro-Wilk test. Normally distributed
data were reported as mean±SD and analyzed using t-tests.
Not normally distributed data were reported as median and
range and were analyzed using Mann–Whitney tests. Sliced
inverse regression (SIR) was used to reduce the dimension-
ality of the density profile measurement and test the
hypothesis that there is a relationship between group as-
signment and CLPDP [25]. Non-parametric correlations
were used to test a linear relationship between parameters.
Significance was set at p<0.05 for all analyses.Results
Signalment of dogs
The breed, sex, sexual status, body condition score (BCS),
and age of the enrolled dogs are shown in Table 1.
There were no statistically significant differences in BCS
among the three groups (p=0.478). Dogs in group 1 were
significantly younger than dogs of group 2A (p<0.0001)Table 1 Signalment of dogs
Parameter Reference populati
Group 1
Pure Breed, n (number of breeds) 23 (19)
Mixed Breed, n 12
Males, n (castrated) 19 (16)
Females, n (spayed) 16 (15)
BCS*, Median (range) 5 (3.5 - 6.0)
Age**, Median (range) 4.4 (1.3 - 11.9)
*BCS = Body Condition Score; Values can range from 1 to 9; 5 is considered ideal a
** Age is reported in years.and group 2B (p<0.0001). There was no statistically signifi-
cant difference in age between groups 2A and 2B (p=1.0).
Also, there were no statistically significant differences in
the dogs’ sex between any of the groups (all p-values
>0.05).Serum TAG and cholesterol concentrations
Serum TAG concentrations of dogs in group 1 (median:
52 mg/dL; range: 27–105 mg/dL), were not significantly dif-
ferent from those of dogs in group 2A (median: 54 mg/dL;
range: 19–108 mg/dL; p value > 0.05; Figure 1). Serum
cholesterol concentrations of dogs in group 1 (median:
221 mg/dL; range: 97–308 mg/dL) were significantly higher
than those of dogs in group 2A (median: 168 mg/dL; range:
74–316 mg/dL; p value= 0.003; Figure 2), although all values
for both groups were within the reference interval.
Serum TAG concentrations of dogs in group 2B ranged
from 218 mg/dL to 3,975 mg/dL (median: 750 mg/dL).
Eleven of the 31 dogs (35%) also had hypercholestero-
lemia. Serum cholesterol concentrations ranged from 158
mg/dL to 575 mg/dL (median: 296 mg/dL). As expected,
both serum TAG (p<0.05) and cholesterol (p<0.05) con-
centrations were significantly higher in dogs of group 2B
than dogs of group 2A (Figures 1 and 2). Similarly, both
serum TAG (p<0.05) and cholesterol (p<0.05) concentra-
tions were significantly higher in dogs of group 2B than
dogs of group 1 (Figures 1 and 2).Continuous lipoprotein density profiling
Eleven separate lipoprotein fractions were identified solely
on density characteristics and not on their functional prop-
erties or composition. In fact, for most of those lipoprotein
fractions, the functional characteristics and composition
are currently unknown. Therefore, all assignments within
the lipoprotein fingerprint to traditional functional classes,
e.g. LDL or HDL, were strictly considered nominal. Density
ranges were classified as R1 to R11 as follows: R1 (d<1.017
g/mL), R2 (d=1.019 to 1.023 g/mL), R3 (d=1.023 to
1.029 g/mL), R4 (d=1.029 to 1.039 g/mL), R5 (d=1.039 to
1.050 g/mL), R6 (d=1.050 to 1.063 g/mL), R7 (d=1.063 toon, Miniature Schnauzers
Group 2A Group 2B
31 (1) 31 (1)
0 0
16 (5) 12 (12)
15 (9) 19 (16)
5 (3.9 – 7.0) 5 (4.9 – 7.9)
9.3 (7 – 12) 9.5 (4.9 – 9.0)
nd 9 is considered obese.
Figure 1 Serum TAG concentrations in dogs of groups 1, 2A,
and 2B. Serum TAG concentrations of dogs in groups 1 and 2A
were all within the reference interval. Serum TAG concentrations of
dogs in group 2B were all above the upper limit of the reference
interval. The dashed line represents the upper limit of the reference
interval and the solid lines represent the median for each group.
Figure 2 Serum cholesterol concentrations in dogs of groups 1,
2A, and 2B. Serum cholesterol concentrations of dogs in groups 1
and 2A were all within the reference interval. Serum cholesterol
concentrations were above the upper limit of the reference interval
for 11 dogs in group 2B. The dashed line represents the upper limit
of the reference interval and the solid lines represent the median for
each group.
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1.133 g/mL), R10 (d=1.133 to 1.156 g/mL), and R11
(d=1.156 to 1.179 g/mL) [26]. Based on a previously pub-
lished classification and based solely on their density character-
istics, these fractions could be classified as: TAG-reach
lipoproteins (TRL; chylomicrons and VLDL; d<1.017 g/mL),
LDL1 (d=1.019 to 1.023 g/mL), LDL2 (d=1.023 to 1.029 g/mL),
LDL3 (d=1.029 to 1.039 g/mL), LDL4 (d=1.039 to 1.050
g/mL), LDL5 (d=1.050 to 1.063 g/mL), HDL2b (d=1.063 to
1.091 g/mL), HDL2a (d=1.091 to 1.110 g/mL), HDL3a
(d=1.110 to 1.133 g/mL), HDL3b (d=1.133 to 1.156 g/mL),
and HDL3c (d=1.156 to 1.179 g/mL), respectively [26].
HDL1 is typically not found in healthy humans but it does
occur in healthy dogs [4,26]. However, it has not been con-
vincingly shown that the previously described canine HDL1
molecule has the same function as human HDL1, and the
density range of canine HDL1 has not been accurately de-
termined (previously published densities vary between
1.025 and 1.1) [4,27]. Determination of the density interval
of that fraction by additional compositional analysis was
not an aim of the present study.
Continuous lipoprotein density profiles of groups 1 and 2A
dogs
Figure 3 shows a representative lipoprotein profile from a
dog in group 1. It is clearly evident that the most abundantlipoprotein fractions are R7 to R11 (d=1.063-1.0179), seen
at a tube coordinates between 23 mm and 31 mm, and
most likely represent HDL. R2 to R6 fractions, most likely
representing LDL, were seen at a tube coordinates between
9 mm and 23 mm, but they were present in very small
amounts, with the exception of R5 and R6 (d = 1.038-
1.063 g/mL). The R1 fraction, most likely representing
TRL (d ≤ 1.017 g/mL) was seen at a tube coordinates of
6 mm to 9 mm and was presumed to contain chylomi-
crons, VLDL, and chylomicron and VLDL remnants. The
TRL fraction was present in very small amounts.
Figure 4 shows a representative CLPDP from a dog in
group 2A. The lipoprotein profiles of Miniature Schnauzers
with serum TAG and cholesterol concentrations within the
reference interval (group 2A) were generally similar to the
ones seen in dogs of group 1 with regard to the abundance
of major lipoprotein classes. However, most dogs in group
2A showed some distinct differences in some lipoprotein
fractions that were further analyzed by SIR.
Sliced inverse regression analysis was used to predict if
differences in lipoprotein profiles were present between
groups 1 and 2A, and also to test whether lipoprotein pro-
files were effective in predicting which group each dog
belonged to. Based on the classification table that docu-
ments the validity of predicted probabilities, the group to
which each dog belonged (i.e., Miniature Schnauzer versus
Figure 3 Representative continuous lipoprotein density profile from a dog of group 1 (normolipemic dogs of breeds other than
Miniature Schnauzers). Intensity refers to the number of pixels of fluorescence emission recorded. The x-axis provides the distance in mm from
the top of the 33 mm ultracentrifuge tube. This dog had serum TAG and cholesterol concentrations within the respective reference intervals. The
most abundant lipoprotein fractions are R7 and R8 (which correspond to a density for HDL), seen at a tube coordinate between 23 mm and 31 mm.
R2 to R6 fractions (corresponding to LDL densities) are present in very small amounts and are seen at a tube coordinate between 9 mm and 23 mm. The
R1 fraction (that corresponds to TRL densities) appears at tube coordinates of 6 mm to 9 mm in very small amounts.
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their lipoprotein profiles in 85% of the cases (Eigen-
values=0.5455; p=0.00017; Figure 5). Specifically, 90% of
Miniature Schnauzers could be classified as Miniature
Schnauzers, and 80% of dogs of other breeds could beFigure 4 Representative continuous lipoprotein density profile from a
descriptions are provided in Figure 4 legend. This Miniature Schnauzer had
reference intervals. The CLPDP of these dogs were generally similar to thos
lipoprotein classes. However, most dogs in group 2A showed more abundclassified as other breeds based on their lipoprotein pro-
files alone. The most important lipoprotein fractions
that served as predictors were the R1, and R5 - R6
(d = 1.038-1.063 g/mL) (Figures 3 and 4). Normolipemic
Miniature Schnauzers had more prominent R1 (likely TRL)dog of group 2A (normolipemic Miniature Schnauzers). Axes
serum TAG and cholesterol concentrations within the respective
e of group 1 (Figure 4) with regard to the abundance of major
ant R1 and less abundant R2 – R6 fractions compared to group 1 dogs.


















Figure 5 One dimensional SIR plot showing classification of
dogs into groups based on CLPDP. The vertical line separates the
two groups based on the measured multidimensional characteristic
(i.e., CLPDP). A linear discriminant analysis (LDA) value generated for
each dog ranks the individual within the group relative to the
vertical line. Individual dogs are represented as dots. The dogs
represented by the dots that are at the bottom of the graph are the
Miniature Schnauzers of group 2A. Their lipoprotein profiles plot
them all to the right of the vertical line, with the exception of 3
dogs (90% of dogs classified correctly). The dogs represented by the
dots at the top of the graph are the dogs of other breeds (group 1).
Twenty-eight of the 35 dogs (80%) were classified as a separate
group to the left of the vertical line. Seven of the 35 dogs were
classified to the right of the vertical line together with the
Miniature Schnauzers.
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had more prominent R5 and R6 peaks (likely nominal
LDL4 and LDL5 peaks).
Continuous lipoprotein density profiles of group 2B dogs
Figures 6a and 6b show representative lipoprotein pro-
files from two dogs in group 2B. Similarly to dogs in
groups 1 and 2A, R7 – R11 fractions (likely correspon-
ding to HDLs) were abundant and R2 – R6 fractions
(likely corresponding to LDLs) were low in this group.
However, dogs of this group had prominent R1 peaks
likely corresponding to the TRL area.
Sliced inverse regression analysis was used to predict if
differences in lipoprotein profiles were present between
groups 2A and 2B, and also to test whether and which lipo-
protein profiles were effective in predicting which group
each dog belonged to. The SIR model showed that the group
to which each dog belonged (i.e., Miniature Schnauzers with
normal versus hypertriacylglyceridemic) could be accu-
rately predicted based on their lipoprotein profiles in 95%
of cases (Eigenvalues=0.7638; p=0.000002; Figure 7). Specifically,
97% of non- hypertriacylglyceridemic Miniature Schnauzers
were correctly classified, and 94% of hypertriacylglyceridemic
Miniature Schnauzers were correctly classifiedbasedon their CLPDP data alone. By far, the most impor-
tant lipoprotein fraction that served as a predictor was
the TRL fraction, which was more prominent in the
dogs with hypertriacylglyceridemia. Fractions corre-
sponding to R3, R4, and R5 (1.023-1.050 g/mL) were
more prominent in Miniature Schnauzers with serum
TAG concentrations within the reference interval
(Figures 6 and 7).Correlations
Non-parametric correlation tests were used to test whether
there was a linear relationship between lipoprotein fractions
that showed significance in the SIR models and serum
TAG and/or cholesterol concentrations. There was a sig-
nificant positive correlation between the nominal TRL (R1)
intensity with both serum TAG concentration (Spearman
r=0.81; 95% CI=0.73-0.87; p<0.0001) and serum cholesterol
concentration (Spearman r=0.61; 95% CI=0.46-0.72;
p<0.0001). There were also significant, but weak, positive
correlations between serum cholesterol concentration and
the nominal LDL2 (R3) fraction (Spearman r=0.42; 95%
CI=0.24-0.58; p<0.0001) and LDL4 (R5) (Spearman r=0.31;
95% CI=0.11-0.48; p=0.0023).Discussion
The method presented here was easy to perform and
proved to be a quick and accurate screening method for
lipoprotein analysis in dogs. Important differences in lipo-
protein profiles between different groups of dogs were
detected with this method. An important and novel finding
of the present study is that Miniature Schnauzers with
serum TAG and cholesterol concentrations within the ref-
erence interval have significantly different lipoprotein pro-
files than those of dogs of various other breeds. In addition,
the present study confirmed and expanded the findings of
previous studies reporting that specific lipoprotein classes
are associated with hypertriacylglyceridemia in Miniature
Schnauzers.
To our knowledge, this is the first study showing that
Miniature Schnauzers with normal serum TAG and choles-
terol concentrations differ significantly in certain lipopro-
tein fractions (R1 and R5 possibly corresponding to TRL
and LDL4) from dogs of various other breeds. A previous
study [10] identified a small number of healthy Miniature
Schnauzers (4 out of 11 studied) that differed in some lipo-
protein fractions (LDL and VLDL) compared with dogs of
other breeds. However, in that particular study, Miniature
Schnauzers were classified as non-lipemic based on the
gross appearance of the plasma rather than a measured
TAG concentration. Indeed, all 4 of the non-lipemic Mini-
ature Schnauzers classified as “different” had mild increases
in plasma TAG concentrations, and therefore, mild lipid
metabolism alterations were present.
Figure 6 Representative continuous lipoprotein density profiles from 2 dogs (a and b) of group 2B (hyperlipidemic Miniature
Schnauzers). As in dogs in groups 1 and 2A, fractions corresponding to nominal HDL densities (R7 to R11) were abundant while fractions
corresponding to nominal LDL densities (R2 to R6) were low in this group. However, dogs of this group had prominent R1 peaks corresponding
to the TRL area. Note the difference in the peak shapes of R1 fractions between the two dogs (a versus b).
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Miniature Schnauzers of group 2A than in dogs of other
breeds, despite the fact that there was no significant differ-
ence in serum TAG concentrations between the two groups
and serum TAG and cholesterol concentrations were
within the reference interval. Interestingly, serum choles-
terol concentrations were found to be significantly higher
in dogs of other breeds compared to Miniature Schnauzers.
This difference might be related to the fact that the R5fraction was significantly higher in dogs of other breeds
compared to Miniature Schnauzers. However, similarly to
serum TAG concentrations, serum cholesterol concentra-
tions were all within the reference interval. The density
interval of R5 was d = 1.039-1.050 g/mL, a density region
that can include LDL4 but also large buoyant HDL [28].
The marked differences in lipoprotein profiles between
Miniature Schnauzers and dogs of other breeds despite the
normal serum TAG and cholesterol concentrations clearly


















Figure 7 One dimensional SIR plot showing classification of
dogs into groups based on CLPDP. The vertical line separates the
two groups based on the measured multidimensional characteristic
(i.e., CLPDP). A linear discriminant analysis (LDA) value generated for
each dog ranks the individual within the group relative to the
vertical line. Individual dogs are represented as dots. Group 2B
hyperlipidemic Miniature Schnauzers are represented by the dots
that are at the bottom of the graph. Their CLPDPs plot them all to
the right of the vertical line, with the exception of one dog with
mildly increased serum TAG concentration (97% of dogs classified
correctly). Group 2A normolipemic Miniature Schnauzers are
represented by the dots at the top of the graph are the Miniature
Schnauzers. All but 2 of the Group 2A dogs are classified as a
separate group to the left of the vertical line (94% of dogs
classified correctly).
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insensitive markers for detecting differences in lipoprotein
metabolism in dogs. These differences in lipoprotein pro-
files could be identified in the vast majority of dogs, as
about 90% of them could be classified to the correct group
based on their lipoprotein profile alone.
The reason for the differences in lipoprotein profiles be-
tween Miniature Schnauzers and dogs of other breeds
with normal serum TAG and cholesterol concentrations is
unknown. The clinical importance of such finding is also
unknown. One plausible scenario for such difference is
that some Miniature Schnauzers might have an early dis-
order in lipoprotein metabolism that has not yet affected
the overall serum TAG and cholesterol concentrations,
but these concentrations might be affected in the future.
This hypothesis is supported by the findings of a previous
study that suggested that hyperlipidemia is an age-related
condition in Miniature Schnauzers [21]. However, this
does not seem a likely explanation in this study because
all Miniature Schnauzers with serum TAG concentrations
within the reference interval enrolled into this study were
above 7 years of age (median age: 9.3 years). Therefore,
these dogs were already of a rather advanced age and un-
likely to develop hypertriacylglyceridemia later in life [21].Another possibility is that the majority of Miniature
Schnauzers differ in their basic lipoprotein metabolism
from dogs of other breeds but only a portion of these dogs
have severe enough lipid metabolism disorders leading to
hyperlipidemia. Also, differences in diet composition or
may have accounted, at least in part, for the differences in
lipoprotein profiles. Differences in the sexual status of the
dogs between groups may also have played a role although
this has not been demonstrated in previous studies.
Clearly, further studies are needed to determine the reason
for this finding and its clinical significance. Moreover, the
ability to rapidly screen the entire density profile of serum
lipoproteins has identified specific density regions amen-
able to further compositional studies that may identify the
mechanism for the distinctive lipoprotein metabolism that
occurs in Miniature Schnauzers.
Lipoprotein profiles of Miniature Schnauzers with
hypertriacylglyceridemia were in agreement with the findings
of previous studies [10]. It is interesting to note that the
main difference between hyperlipidemic and normolipidemic
Miniature Schnauzers was a significant increase of the R1
(TRL) fraction in hyperlipidemic Miniature Schnauzers,
and there was a strong correlation between TRLs and
serum TAG concentrations. Similarly to previous studies,
there was no difference in the HDL fractions [10]. Interes-
tingly, the present study showed that a specific fraction
(R3 likely corresponding to the density of LDL2) was
significantly decreased in Miniature Schnauzers with
hyperlipidemia.
Another interesting observation is that the CLPDP of
Miniature Schnauzers with hyperlipidemia, although diffe-
rent in their lipoprotein profiles from Miniature Schnauzers
without hyperlipidemia, was rather diverse and there were
some distinct differences among dogs in the same group.
These differences were not always related to the different
degrees of hyperlipidemia in these dogs. For example, many
hyperlipidemic Miniature Schnauzers had 2 distinct peaks
in their TRL fractions (Figure 7), while others only had one
(Figure 6). These 2 peaks likely represent chylomicrons and
VLDLs, which have slightly different densities. This is in
agreement with findings of an older study [10], in which it
was shown that some hyperlipidemic Miniature Schnauzers
had increases in VLDLs only, while others had increases in
both VLDLs and chylomicrons. It is not known why some
of the hyperlipidemic Miniature Schnauzers have only one
TRL fraction affected while others have 2. In addition, as
shown in previous studies [10,21], a fraction if these dogs
had increases in serum cholesterol concentrations. Thus, it
is obvious that hyperlipidemia in Miniature Schnauzers is
not a phenotypically uniform disease. This might be the re-
sult of the effect of environmental factors or maybe due to
genetic heterogeneity.
Miniature Schnauzers of either group were significantly
older than the dogs of other breeds used in this study.
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pidemia in Miniature Schnauzers is known to be an age-
related condition and, therefore, dogs in group 2 had to be
of older age in order to have developed their phenotype
with a high degree of probability if in fact they were to de-
velop hypertriacylglyceridemia. For example, in one study,
only 16% of Miniature Schnauzers between 1 and 3 years
of age were hypertriacylcerolemic, while 78% of Miniature
Schnauzers >9 years of age were hypertriacylglycerolemic.
No association between age and serum TAG or choles-
terol concentrations have been reported or suspected in
dogs of breeds other than Miniature Schnauzers.
It needs to be pointed out that the present method as
described in the present study does not allow detailed
characterization of the components of each lipoprotein
fraction. As mentioned above, the lipoprotein fractions
were identified solely based on density characteristics and
not on their functional properties or composition, which
are to a large degree unknown in dogs. Therefore, all as-
signments within the lipoprotein fingerprint to traditional
functional classes, e.g. LDL or HDL, were strictly consi-
dered nominal. Further studies are warranted to investi-
gate the exact content and functional properties of all
canine lipoprotein fractions.
Conclusions
In conclusion, the results of the present study suggest that
density gradient ultracentrifugation using NaBiEDTA is a
useful screening method for the study of lipoprotein pro-
files in dogs. Therefore, this method could potentially be
used for diagnostic purposes for the separation of dogs
suspected of having lipoprotein abnormalities from
healthy dogs. Important differences in lipoprotein profiles
can be detected with this method even among dogs that
have serum TAG and cholesterol concentrations within
the reference interval, and dogs belonging to different
groups can be effectively separated based on their lipopro-
tein profiles using discriminant analysis. Miniature
Schnauzers with serum TAG and cholesterol concentra-
tions within the reference interval had significantly diffe-
rent lipoprotein profiles (mainly with regard to fractions
R1 and R5, which based on density characteristics, corres-
pond to TRL and LDL4) than dogs of various other breeds.
In addition, it was further established that specific lipopro-
tein fractions (R1 and R3, which based on density charac-
teristics, correspond to TRL and LDL2) are associated
with hypertriacylglyceridemia in Miniature Schnauzers.
Changes in these lipoprotein fractions are not always uni-
form among Miniature Schnauzers with hyperlipidemia.
Further studies are needed to evaluate the usefulness of
density gradient ultracentrifugation using NaBiEDTA in
evaluating hyperlipidemia of other causes in dogs, and to
establish the clinical significance of differences in lipopro-
tein profiles in Miniature Schnauzers.Endnotes
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